ArticleSAGE open medical case reports2025
Recalcitrant vulvar lichen planus cleared on abrocitinib: A case report.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of JAK Inhibitors in Lichen Planus: A Systematic Review of the Available Clinical Evidence.Mediators of inflammation · 2026Pooled it
- Rapid resolution of refractory cutaneous lichen planus with abrocitinib.JAAD case reports · 2026Article
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen planus is a chronic inflammatory disorder, with vulvar variants often resistant to multiple treatments. The primary therapeutic goals for vulvar lichen planus are to prevent scarring and the development of squamous cell carcinoma. Management also involves treating associated symptoms such as pruritus and pain. This report describes a 50-year-old female with treatment-resistant hypertrophic and erosive vulvar lichen planus. Despite extensive trials of various therapies, the patient experienced symptoms of pruritus, pain, and repeated flares, significantly affecting her quality of life. Abrocitinib, a highly selective Janus kinase 1 inhibitor, was added to her treatment regimen, leading to a 95% resolution of lesions and substantial improvement in quality of life. This case highlights the potential of abrocitinib as an effective, novel off-label treatment for recalcitrant vulvar lichen planus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.